Trends in immunotherapy use and survival impact in stage IV non-small cell lung cancer.

被引：0
|
作者：
Otaibi, Zachary
Kamran, Amir
Wegner, Rodney E.
Colonias, Athanasios
Weksler, Benny
Finley, Gene Grant
机构：
[1] Allegheny Hlth Network, Pittsburgh, PA USA
[2] Allegheny Hlth Network, Inst Canc, Pittsburgh, PA USA
[3] Allegheny Hlth Network, Inst Canc, Div Radiat Oncol, Pittsburgh, PA USA
[4] Allegheny Gen Hosp, Sewickley, PA USA
[5] Allegheny Hlth Network, Dept Cardiothorac Surg, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20715
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Timing of immunotherapy in stage IV non-small cell lung cancer.
    Komiya, Takefumi
    Zhu, Junjia
    Takamori, Shinkichi
    Greenberg, Max
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Use of chemotherapy for patients with stage IV non-small cell lung cancer.
    Waqar, Sadaf Huma
    Waqar, Saiama Naheed
    Devarakonda, Siddhartha
    Gao, Feng
    Robinson, Cliff Grant
    Puri, Varun
    Govindan, Ramaswamy
    Morgensztern, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Trends in chemotherapy use and survival for patients with metastatic non-small cell lung cancer.
    Byrne, B
    Crawford, J
    Gay, G
    Bonner, J
    Gaspar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 634S - 634S
  • [4] Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
    Naqash, A. R.
    Jonnalagadda, S.
    Macherla, S.
    Polsani, S.
    Muzaffar, M.
    Cherry, C.
    Karim, N. Abdel
    Walker, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S464 - S464
  • [5] Extending Survival of Stage IV Non-Small Cell Lung Cancer
    Carnio, Simona
    Novello, Silvia
    Mele, Teresa
    Levra, Matteo Giaj
    Scagliotti, Giorgio Vittorio
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : 69 - 92
  • [6] Is survival improving in stage IV non-small cell lung cancer?
    Birnbaum, A. E.
    Ng, T.
    O'Connor, B.
    Plette, A.
    Berz, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Nivolumab timing as a major survival predictor in patients with stage IV non-small cell lung cancer.
    Karaboue, Abdoulaye
    Collon, Thierry
    Bodiguel, Viviane
    Cucherousset, Joel
    Innominato, Pasquale
    Bouchahda, Mohamed
    Adam, Rene
    Levi, Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Effect of delaying chemotherapy on survival outcomes in the treatment of stage IV non-small cell lung cancer.
    Mozayen, Mohammad
    Alsharedi, Mohamed Farouq
    Mehmi, Inderjit
    Gress, Todd W.
    Tirona, Maria R. B. Tria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer.
    Fei, Naomi
    Attia, Christina
    Almubarak, Mohammed
    Ma, Patrick C.
    Mattes, Malcolm David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer
    Vazquez-Urrutia, Jorge Raul
    Greenberg, Max
    Zhu, Junjia
    Takamori, Shinkichi
    Komiya, Takefumi
    WORLD JOURNAL OF ONCOLOGY, 2024, 15 (05) : 769 - 776
12345